229 related articles for article (PubMed ID: 22041138)
1. In vitro assessment of the allelic variants of cytochrome P450.
Hiratsuka M
Drug Metab Pharmacokinet; 2012; 27(1):68-84. PubMed ID: 22041138
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
4. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
Chang TK; Yu L; Goldstein JA; Waxman DJ
Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
[TBL] [Abstract][Full Text] [Related]
5. Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes.
Gao N; Tian X; Fang Y; Zhou J; Zhang H; Wen Q; Jia L; Gao J; Sun B; Wei J; Zhang Y; Cui M; Qiao H
Eur J Pharm Sci; 2016 Sep; 92():86-97. PubMed ID: 27339126
[TBL] [Abstract][Full Text] [Related]
6. Update: genetic polymorphism of drug metabolizing enzymes in humans.
Tanaka E
J Clin Pharm Ther; 1999 Oct; 24(5):323-9. PubMed ID: 10583694
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms.
Renwick AB; Mistry H; Ball SE; Walters DG; Kao J; Lake BG
Xenobiotica; 1998 Apr; 28(4):337-48. PubMed ID: 9604298
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of a novel phosphodiesterase-IV inhibitor (V11294) by human hepatic cytochrome P450 forms.
Subrahmanyam V; Renwick AB; Walters DG; Price RJ; Tonelli AP; Lake BG
Xenobiotica; 2002 Jun; 32(6):521-34. PubMed ID: 12160484
[TBL] [Abstract][Full Text] [Related]
9. Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma.
Zhou J; Wen Q; Li SF; Zhang YF; Gao N; Tian X; Fang Y; Gao J; Cui MZ; He XP; Jia LJ; Jin H; Qiao HL
Oncotarget; 2016 Aug; 7(31):50612-50623. PubMed ID: 27203676
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.
Solus JF; Arietta BJ; Harris JR; Sexton DP; Steward JQ; McMunn C; Ihrie P; Mehall JM; Edwards TL; Dawson EP
Pharmacogenomics; 2004 Oct; 5(7):895-931. PubMed ID: 15469410
[TBL] [Abstract][Full Text] [Related]
11. Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies.
Schmider J; Greenblatt DJ; von Moltke LL; Harmatz JS; Duan SX; Karsov D; Shader RI
Pharmacology; 1996 Feb; 52(2):125-34. PubMed ID: 8851634
[TBL] [Abstract][Full Text] [Related]
12. Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach.
Caspar AT; Meyer MR; Maurer HH
Toxicol Lett; 2018 Mar; 285():1-8. PubMed ID: 29277574
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
[TBL] [Abstract][Full Text] [Related]
14. Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine.
Fang J; Coutts RT; McKenna KF; Baker GB
Naunyn Schmiedebergs Arch Pharmacol; 1998 Nov; 358(5):592-9. PubMed ID: 9840430
[TBL] [Abstract][Full Text] [Related]
15. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology.
Yoshitomi S; Ikemoto K; Takahashi J; Miki H; Namba M; Asahi S
Toxicol In Vitro; 2001 Jun; 15(3):245-56. PubMed ID: 11377097
[TBL] [Abstract][Full Text] [Related]
16. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
Velazquez MNR; Parween S; Udhane SS; Pandey AV
Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
[TBL] [Abstract][Full Text] [Related]
17. Polymorphic drug metabolizing CYP-enzymes--a pathogenic factor in oral lichen planus?
Kragelund C; Hansen C; Reibel J; Nauntofte B; Broesen K; Pedersen AM; Smidt D; Eiberg H; Torpet LA
J Oral Pathol Med; 2009 Jan; 38(1):63-71. PubMed ID: 19192051
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
19. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
[TBL] [Abstract][Full Text] [Related]
20. [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10.
Rodrigues AD; Kukulka MJ; Roberts EM; Ouellet D; Rodgers TR
Drug Metab Dispos; 1996 Jan; 24(1):126-36. PubMed ID: 8825200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]